Evidence map›Paper›PMID 39865710›Full record

ArticleHeadache2025

Erenumab in a patient with persistent headaches after subarachnoid hemorrhage: A case report of an effective treatment.

Ajay Gandhi, Travis R Quinoa, Eric Geller, Priyank Khandelwal, Pankaj K Agarwalla

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Headache, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Headache After Stroke: An Update for the Clinician.Current neurology and neuroscience reports · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ajay GandhiDepartment of Neurological Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
Travis R QuinoaDepartment of Neurological Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.ORCID 0000-0002-5135-3610
Eric GellerInstitute of Neurology, Livingston, New Jersey, USA.
Priyank KhandelwalDepartment of Neurological Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
Pankaj K AgarwallaDepartment of Neurological Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A patient with persistent refractory headaches from aneurysmal subarachnoid hemorrhage was treated with monthly erenumab injections, a monoclonal antibody to the calcitonin gene-related peptide (CGRP) receptor. These injections decreased the frequency and severity of the patient's debilitating headaches from daily to once or twice per month with positive improvement in function and quality of life. To our knowledge, this is the first reported case in the literature of a patient with persistent post-subarachnoid hemorrhage headache that was successfully treated with an antibody against the CGRP receptor. This case report highlights the role of CGRP in post-subarachnoid hemorrhage headaches and the potential role for CGRP pathway-based therapies as an effective treatment.

Indexed as

Antibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsHeadacheSubarachnoid HemorrhageFemaleHumansMaleMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonistserenumabcalcitonin gene–related peptideerenumabheadachemigrainesubarachnoid hemorrhagetrigeminovascular system

Identifiers

PMID39865710
PMCPMC11794963

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.